Mutual of America Capital Management LLC Has $24.62 Million Position in Pfizer Inc. (NYSE:PFE)

Mutual of America Capital Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 754,330 shares of the biopharmaceutical company’s stock after purchasing an additional 10,589 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Pfizer were worth $24,621,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. State Street Corp raised its position in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 291,791,099 shares of the biopharmaceutical company’s stock valued at $11,432,375,000 after acquiring an additional 1,521,665 shares in the last quarter. Capital World Investors raised its position in Pfizer by 13.4% during the fourth quarter. Capital World Investors now owns 188,715,390 shares of the biopharmaceutical company’s stock valued at $7,393,867,000 after acquiring an additional 22,232,056 shares in the last quarter. Geode Capital Management LLC raised its position in Pfizer by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 89,043,762 shares of the biopharmaceutical company’s stock valued at $3,482,382,000 after acquiring an additional 1,630,039 shares in the last quarter. Bank of New York Mellon Corp raised its position in Pfizer by 4.9% during the fourth quarter. Bank of New York Mellon Corp now owns 59,763,050 shares of the biopharmaceutical company’s stock valued at $2,341,517,000 after acquiring an additional 2,783,991 shares in the last quarter. Finally, Norges Bank bought a new position in Pfizer during the fourth quarter valued at approximately $2,326,225,000. Institutional investors and hedge funds own 69.91% of the company’s stock.

In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $38.35, for a total transaction of $83,641.35. Following the sale, the senior vice president now owns 9,647 shares in the company, valued at $369,962.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Douglas M. Lankler sold 65,000 shares of Pfizer stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the sale, the executive vice president now owns 135,375 shares in the company, valued at approximately $5,123,943.75. The disclosure for this sale can be found here. Company insiders own 0.08% of the company’s stock.

Shares of Pfizer stock traded up $0.24 during midday trading on Friday, hitting $37.50. The company had a trading volume of 14,885,114 shares, compared to its average volume of 22,354,300. The business’s 50 day simple moving average is $36.51 and its two-hundred day simple moving average is $36.84. The stock has a market cap of $206.97 billion, a PE ratio of 13.39, a P/E/G ratio of 2.72 and a beta of 0.71. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $44.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.09. The business had revenue of $12.03 billion for the quarter, compared to the consensus estimate of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. Pfizer’s quarterly revenue was down 8.3% on a year-over-year basis. During the same quarter last year, the company posted $0.85 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.81 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 8th will be paid a $0.38 dividend. The ex-dividend date of this dividend is Thursday, May 7th. This represents a $1.52 annualized dividend and a dividend yield of 4.05%. Pfizer’s payout ratio is 51.53%.

Several equities analysts recently weighed in on PFE shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price objective on shares of Pfizer in a research report on Thursday, March 19th. Royal Bank of Canada reissued a “buy” rating and issued a $44.00 price target on shares of Pfizer in a research report on Monday, April 27th. Mizuho reissued a “buy” rating and issued a $42.00 price target on shares of Pfizer in a research report on Monday, May 18th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target on the stock. in a research report on Monday, May 4th. Finally, Morgan Stanley dropped their price target on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 2nd. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $41.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Yield Curve

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.